Effect and mechanism of panaxoside Rg1 on neovascularization in myocardial infarction rats.
OBJECTIVE
To investigate the effects and mechanisms of panaxoside Rg1 on the new vessel formation in acute myocardial infarction (AMI) rats.


METHODS
The AMI model of male Sprague-Dawley (SD) rats was established, and rats were randomly divided into the AMI model group, the treatment group of panaxoside Rg1, the placebo group and the treatment group of panaxoside Rg1 plus rapamycin. Cardiac creatases were determined with 1 mL blood drawn from vena caudalis of the rats 48 h after the model was successfully made. After 4 weeks, Evans blue was injected into the aorta roots of the rats, and then, red tetrazoline was dyed again and the myocardial infarction area was evaluated. The microvessel density (MVD) of infarction area was determined by the immunohistochemistry of CD31; enzyme-linked immunosorbent assay (ELISA) was used to detect the protein content of CD31 and hypoxia inducible factor-1alpha (HIF-1alpha) of the infarction area.


RESULTS
The MVD in the infarction area and the contents of CD31 and HIF-1alpha in the Rg1 treatment group were higher than those in the AMI model group significantly (P<0.05). The cardiac creatase and infarction area were lower in the Rg1 treatment group than those in the AMI model group significantly (P<0.05). The above effects, however, disappeared when rapamycin, the antagonist of mammalian target of rapamycin (mTOR), was administered simultaneously.


CONCLUSIONS
Panaxoside Rg1 could increase the expression of HIF-1alpha and CD31 of myocardium and stimulate the angiogenesis. The above mentioned role of panaxoside Rg1 might be related to the excitation of mTOR receptor.
Wang
Xiao-dong
XD
Department of Cardiac Surgery, the First Affiliated Hospital, China Medical University, Shenyang (110001), China.
Gu
Tian-xiang
TX
Shi
En-Yi
EY
Lu
Chun-mao
CM
Wang
Chun
C
D000818:Animals; D002452:Cell Count; D003097:Collateral Circulation / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D036145:Ginsenosides / Q000008:administration & dosage / Q000494:pharmacology*; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000378:metabolism; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism / Q000502:physiology; D008297:Male; D055806:Microvessels / Q000473:pathology; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D010919:Placebos; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000378:metabolism; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism / Q000502:physiology; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D015398:Signal Transduction / Q000187:drug effects; D020123:Sirolimus / Q000008:administration & dosage / Q000494:pharmacology; D058570:TOR Serine-Threonine Kinases
D036145:Ginsenosides; C497444:Hif1a protein, rat; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D047908:Intracellular Signaling Peptides and Proteins; D010919:Placebos; D019408:Platelet Endothelial Cell Adhesion Molecule-1; C546845:mTOR protein, rat; D017346:Protein Serine-Threonine Kinases; D058570:TOR Serine-Threonine Kinases; C035054:ginsenoside Rg1; D020123:Sirolimus
J Clin Endocrinol Metab. 2002 Aug;87(8):3691-5
12161497
Am J Pathol. 1995 Jul;147(1):9-19
7541613
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2004 Feb;24(2):127-9, 132
15015445
Genes Dev. 2004 Aug 15;18(16):1926-45
15314020
Biochem Biophys Res Commun. 2006 Oct 27;349(3):987-94
16962070
Brain Res. 2004 Sep 17;1021(1):41-53
15328030
Nature. 2006 Aug 17;442(7104):779-85
16915281
Pharmacol Toxicol. 2003 Dec;93(6):275-83
14675461
Circulation. 2006 Aug 15;114(7):637-44
16894033
Yao Xue Xue Bao. 2003 Oct;38(10):735-8
14730894
Int J Pharm. 2007 Jan 10;328(2):168-76
16962729
J Biol Chem. 2007 Jul 13;282(28):20534-43
17502379
Circulation. 1995 Feb 1;91(3):755-63
7530174
Blood. 2006 Jan 15;107(2):584-90
16189264
Circulation. 2004 Aug 17;110(7):796-802
15302788
FEBS Lett. 2007 Oct 16;581(25):4977-82
17919602
Circulation. 2008 Sep 30;118(14 Suppl):S145-52
18824746